HLS Therapeutics Inc. (TSX: HLS)
Health Care · Pharmaceuticals · CA
CA$4.09
+5.68% today · -25.9% 1Y
HLS Therapeutics Inc. (TSX: HLS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $87.26M and employs 85 people.
Over the last twelve months the share price has lost 25.9%, trading between 3.56 and 5.64.
Tweenvest scores HLS Therapeutics Inc. across four factors: quality 67/100, value 78/100, growth 18/100. Its strongest factor is value.
HLS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $87.26M
- Revenue (TTM)
- $56.24M
- P/E
- —
- EPS
- -0.27
- Dividend yield
- —
- Beta (5Y)
- 0.76
- 52-week high
- CA$5.64
- 52-week low
- CA$3.56
- Avg volume (3M)
- —
- Shares outstanding
- 30.44M
- Employees
- 85
- Next earnings
- —
About HLS Therapeutics Inc.
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
- ISIN
- CA40390B1094
- Listed since
- Mar 14, 2018
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Neumora Therapeutics, Inc.NasdaqGS: NMRA | $89.38M | $0.44 | -8.05% |
| Dar Al Dawa Development and Investment Co. Ltd.ASE: DADI | $88.16M | JD1.25 | +1.63% |
| Hyphens Pharma International LimitedCatalist: 1J5 | $88.02M | S$0.37 | +2.82% |
| Kilitch Drugs (India) LimitedBSE: 524500 | $87.67M | Rs242.70 | +12.34% |
| Lee's Pharmaceutical Holdings LimitedSEHK: 950 | $86.29M | HK$1.15 | -1.71% |
| Jeil Pharma Holdings IncKOSE: A002620 | $86.21M | ₩7,550.00 | +1.34% |
| Dicot Pharma ABOM: DICOT | $86.03M | Skr0.25 | -1.21% |
| Ahn-Gook Pharmaceutical Co., Ltd.KOSDAQ: A001540 | $85.72M | ₩10,140.00 | +3.36% |
Figures last refreshed Oct 11, 2026.